INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Molecules

Orbus Therapeutics

Skyhawk Therapeutics

Palvella Therapeutics

View Full Portfolio

Featured News

News | July 16, 2019

Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk

Read More

News | July 8, 2019

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster of partners out to drug RNA

Read More

News | June 10, 2019

Aptinyx Reports Top-line Data from Phase 2 in Patients with Fibromyalgia

Read More

View All